Market Closed -
Nasdaq
04:00:00 2024-05-28 pm EDT
|
5-day change
|
1st Jan Change
|
9.24
USD
|
-3.25%
|
|
+10.39%
|
+11.19%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,165
|
2,818
|
952.1
|
728.5
|
485.3
|
563.7
|
-
|
-
|
Enterprise Value (EV)
1 |
1,165
|
2,818
|
722.6
|
301.3
|
147.6
|
378.2
|
376.2
|
343.4
|
P/E ratio
|
-7.95
x
|
-33.3
x
|
-5.95
x
|
-3.2
x
|
-1.76
x
|
-3.59
x
|
-2.95
x
|
-3.35
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
681
x
|
228
x
|
12.3
x
|
54.1
x
|
11.1
x
|
EV / Revenue
|
-
|
-
|
-
|
282
x
|
69.3
x
|
8.25
x
|
36.1
x
|
6.77
x
|
EV / EBITDA
|
-
|
-
|
-4.49
x
|
-1.36
x
|
-0.58
x
|
-2.1
x
|
-1.66
x
|
-1.75
x
|
EV / FCF
|
-24.6
x
|
-33.2
x
|
-5.25
x
|
-18.8
x
|
-0.72
x
|
-2.33
x
|
-1.75
x
|
-1.61
x
|
FCF Yield
|
-4.07%
|
-3.01%
|
-19%
|
-5.33%
|
-139%
|
-43%
|
-57.2%
|
-62.1%
|
Price to Book
|
-
|
-
|
4.04
x
|
2.46
x
|
-
|
1.18
x
|
1.62
x
|
1.82
x
|
Nbr of stocks (in thousands)
|
30,536
|
31,922
|
32,462
|
42,827
|
58,394
|
59,024
|
-
|
-
|
Reference price
2 |
38.16
|
88.29
|
29.33
|
17.01
|
8.310
|
9.550
|
9.550
|
9.550
|
Announcement Date
|
3/26/20
|
3/30/21
|
3/29/22
|
3/30/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
1.069
|
2.13
|
45.83
|
10.42
|
50.72
|
EBITDA
1 |
-
|
-
|
-160.8
|
-221.9
|
-255.2
|
-180.5
|
-226.5
|
-196.3
|
EBIT
1 |
-44.5
|
-83.28
|
-165.3
|
-228
|
-263.5
|
-182.1
|
-236.3
|
-238.2
|
Operating Margin
|
-
|
-
|
-
|
-21,324.23%
|
-12,369.06%
|
-397.36%
|
-2,267.06%
|
-469.53%
|
Earnings before Tax (EBT)
1 |
-43.13
|
-81.36
|
-165.2
|
-221.1
|
-245.7
|
-165.3
|
-233.8
|
-236.7
|
Net income
1 |
-43.13
|
-81.36
|
-165.2
|
-221.1
|
-246.4
|
-162.9
|
-231.7
|
-236.7
|
Net margin
|
-
|
-
|
-
|
-20,683.07%
|
-11,568.83%
|
-355.48%
|
-2,222.12%
|
-466.7%
|
EPS
2 |
-4.800
|
-2.650
|
-4.930
|
-5.320
|
-4.710
|
-2.660
|
-3.242
|
-2.852
|
Free Cash Flow
1 |
-47.45
|
-84.8
|
-137.6
|
-16.06
|
-204.6
|
-162.7
|
-215.2
|
-213.2
|
FCF margin
|
-
|
-
|
-
|
-1,502.25%
|
-9,606.2%
|
-354.88%
|
-2,063.85%
|
-420.38%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/20
|
3/30/21
|
3/29/22
|
3/30/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
0.366
|
0.331
|
0.372
|
0.522
|
0.448
|
0.509
|
0.651
|
0.497
|
54.31
|
0.39
|
0.3431
|
0.5167
|
0.5167
|
EBITDA
|
-
|
-
|
-
|
-
|
-54.37
|
-
|
-66.04
|
-64.5
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-50.68
|
-51.96
|
-59.22
|
-60.51
|
-56.26
|
-63.9
|
-68.21
|
-66.76
|
-65.12
|
-53.86
|
0.2901
|
-53.84
|
-54.98
|
-54.38
|
-56.38
|
Operating Margin
|
-
|
-
|
-16,181.42%
|
-18,281.57%
|
-15,124.73%
|
-12,240.61%
|
-15,225%
|
-13,115.91%
|
-10,002.92%
|
-10,836.22%
|
0.53%
|
-13,806.06%
|
-16,023.56%
|
-10,524.8%
|
-10,912.19%
|
Earnings before Tax (EBT)
1 |
-50.64
|
-51.89
|
-58.6
|
-58.04
|
-52.58
|
-59.22
|
-64.31
|
-61.75
|
-60.45
|
-49.82
|
11.21
|
-51.1
|
-52.48
|
-51.83
|
-54.03
|
Net income
1 |
-50.64
|
-51.89
|
-58.6
|
-58.04
|
-52.58
|
-59.31
|
-64.42
|
-61.99
|
-60.7
|
-49.82
|
10.68
|
-51.13
|
-52.35
|
-51.83
|
-54.03
|
Net margin
|
-
|
-
|
-16,009.56%
|
-17,533.84%
|
-14,133.33%
|
-11,361.88%
|
-14,380.13%
|
-12,178.59%
|
-9,323.35%
|
-10,023.34%
|
19.66%
|
-13,110.08%
|
-15,256.15%
|
-10,031.26%
|
-10,457.35%
|
EPS
2 |
-1.500
|
-1.530
|
-1.330
|
-1.320
|
-1.190
|
-1.330
|
-1.430
|
-1.040
|
-1.010
|
-0.8300
|
0.1603
|
-0.8404
|
-0.8016
|
-0.8467
|
-0.7933
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/29/22
|
5/9/22
|
8/8/22
|
11/3/22
|
3/30/23
|
5/12/23
|
8/3/23
|
11/13/23
|
3/7/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
230
|
427
|
338
|
185
|
187
|
220
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-47.5
|
-84.8
|
-138
|
-16.1
|
-205
|
-163
|
-215
|
-213
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-52.7%
|
-83.1%
|
-100%
|
-94.3%
|
-242%
|
-156%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-54.5%
|
-52.6%
|
-27.4%
|
-32.5%
|
-29.4%
|
Assets
1 |
-
|
-
|
-
|
405.8
|
468.5
|
594.9
|
713.7
|
805.3
|
Book Value Per Share
2 |
-
|
-
|
7.250
|
6.910
|
-
|
8.110
|
5.890
|
5.260
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-0.1400
|
-3.670
|
-1.460
|
-2.460
|
-
|
Capex
1 |
2.34
|
17.5
|
13.2
|
10.2
|
12.4
|
12.1
|
12.7
|
12.9
|
Capex / Sales
|
-
|
-
|
-
|
954.72%
|
581.27%
|
26.29%
|
122.01%
|
25.41%
|
Announcement Date
|
3/26/20
|
3/30/21
|
3/29/22
|
3/30/23
|
3/7/24
|
-
|
-
|
-
|
Last Close Price
9.55
USD Average target price
21.4
USD Spread / Average Target +124.08% Consensus |
1st Jan change
|
Capi.
|
---|
| +11.19% | 564M | | +9.83% | 118B | | +10.80% | 106B | | -10.84% | 23.4B | | -1.69% | 22.1B | | -10.23% | 18.34B | | -41.92% | 16.59B | | -15.11% | 15.97B | | +6.62% | 14.03B | | +17.53% | 11.67B |
Bio Therapeutic Drugs
|